CIDP

Argenx will present over 40 abstracts at the 2025 AANEM/MGFA meeting, highlighting data on VYVGART (IV and SC) and empasiprubart. Key presentations include ADAPT SERON results showing VYVGART’s efficacy in AChR antibody-negative gMG, interim ADAPT Jr data in juvenile gMG, and Phase 2/3 empasiprubart programs for CIDP and MMN (EMVIGORATE, EMNERGIZE, EMPASSION). Real-world evidence and long-term data will also be presented, reinforcing VYVGART’s sustained benefit. The conference will address concerns of allergic risks and infection management.

Halozyme Therapeutics announced the European Commission’s approval of argenx’s VYVGART subcutaneous injection, utilizing Halozyme’s ENHANZE drug delivery technology, for chronic inflammatory demyelinating polyneuropathy (CIDP). This approval, based on positive ADHERE trial data, marks a significant advancement for CIDP treatment and expands drug access across Europe. VYVGART, the first targeted IgG Fc-antibody fragment for CIDP, represents a new treatment mechanism in over three decades. The SC injection can be administered by patients, caregivers, or healthcare professionals.